<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BCL6 is a transcriptional repressor that is overexpressed in diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The N-terminal POZ domain of BCL6 interacts with transcriptional corepressors and targeting these associations is a promising therapeutic strategy </plain></SENT>
<SENT sid="2" pm="."><plain>Previous structural studies of the BCL6 POZ domain have used a mutant form because of the low solubility of the <z:mp ids='MP_0002169'>wild-type</z:mp> recombinant protein </plain></SENT>
<SENT sid="3" pm="."><plain>A method for the purification and crystallization of the <z:mp ids='MP_0002169'>wild-type</z:mp> BCL6 POZ domain is described and the crystal structure to 2.1 A resolution is reported </plain></SENT>
<SENT sid="4" pm="."><plain>This will be relevant for the design of therapeutics that target BCL6 POZ-domain interaction interfaces </plain></SENT>
</text></document>